Cor Medix Inc. CRMD
We take great care to ensure that the data presented and summarized in this overview for CorMedix Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRMD
View all-
Vanguard Group Inc Valley Forge, PA3.98MShares$45.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$40.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X03.47MShares$39.4 Million0.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.32MShares$37.7 Million0.74% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.81MShares$20.5 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.72MShares$19.5 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.26MShares$14.3 Million0.05% of portfolio
-
Ubs Group Ag1.09MShares$12.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY844KShares$9.57 Million0.0% of portfolio
Latest Institutional Activity in CRMD
Top Purchases
Top Sells
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Transactions at CRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
34,000
-41.23%
|
$408,000
$12.0 P/Share
|
|
Dec 09
2025
|
Janet Dillione Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+18.68%
|
$238,000
$7.59 P/Share
|
|
Dec 09
2025
|
Steven W Lefkowitz Director |
SELL
Open market or private sale
|
Direct |
40,000
-33.2%
|
$440,000
$11.88 P/Share
|
|
Dec 02
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
46,657
-49.05%
|
$466,570
$10.0 P/Share
|
|
Dec 02
2025
|
Janet Dillione Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,657
+16.76%
|
$186,628
$4.0 P/Share
|
|
Nov 24
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
26,343
-35.21%
|
$237,087
$9.93 P/Share
|
|
Nov 24
2025
|
Janet Dillione Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,343
+9.22%
|
$79,029
$3.72 P/Share
|
|
Nov 14
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
30,000
-38.23%
|
$330,000
$11.42 P/Share
|
|
Oct 23
2025
|
Myron Kaplan Director |
BUY
Open market or private purchase
|
Direct |
25,000
+11.06%
|
$275,000
$11.02 P/Share
|
|
Sep 16
2025
|
Gregory Scott Duncan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,333
+25.81%
|
$106,664
$8.32 P/Share
|
|
Sep 12
2025
|
Alan W Dunton Director |
SELL
Open market or private sale
|
Direct |
10,000
-19.9%
|
$130,000
$13.13 P/Share
|
|
Sep 12
2025
|
Alan W Dunton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.6%
|
$30,000
$3.55 P/Share
|
|
Sep 12
2025
|
Joseph Todisco Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-8.94%
|
$650,000
$13.0 P/Share
|
|
Sep 12
2025
|
Joseph Todisco Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.2%
|
$150,000
$3.47 P/Share
|
|
Sep 11
2025
|
Elizabeth Masson Hurlburt Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
41,121
-18.85%
|
$534,573
$13.08 P/Share
|
|
Sep 11
2025
|
Elizabeth Masson Hurlburt Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,121
+15.86%
|
$41,121
$1.45 P/Share
|
|
Sep 09
2025
|
Elizabeth Masson Hurlburt Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,876
-6.78%
|
$167,388
$13.51 P/Share
|
|
Sep 09
2025
|
Elizabeth Masson Hurlburt Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,876
+6.35%
|
$12,876
$1.45 P/Share
|
|
Sep 09
2025
|
Kaufman Beth Zelnick Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
50,000
-10.87%
|
$650,000
$13.12 P/Share
|
|
Sep 09
2025
|
Kaufman Beth Zelnick Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+17.83%
|
$150,000
$3.3 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 847K shares |
|---|---|
| Exercise of conversion of derivative security | 364K shares |
| Open market or private purchase | 25K shares |
| Open market or private sale | 341K shares |
|---|---|
| Payment of exercise price or tax liability | 121K shares |